Lagerlof I, Fohlin H, Enblad G, Glimelius B, et al. Limited, But Not Eliminated, Excess Long-Term Morbidity in Stage I-IIA Hodgkin Lymphoma Treated With Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine and Limited-Field Radiotherapy. J Clin Oncol 2022 Jan 25:JCO2102407. doi: 10.1200/JCO.21.02407.
PMID: 35077204